10

15

20

-106-

#### **CLAIMS**

#### What is claimed is:

1. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Formula I

wherein

Ra is hydrogen, C1-C6 alkyl, or -CC1-C6 alkyl;

n is 0 to 5 inclusive;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently hydrogen, halogen, -OH, -NH<sub>2</sub>, NR<sup>b</sup>R<sup>c</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -NO<sub>2</sub>, -OC<sub>1</sub>-C<sub>12</sub> alkyl, -C1-C8 alkyl, -CF3, -CN, -OCH2 phenyl, -OCH2-substituted phenyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, -O-phenyl, -O-substituted phenyl,

-CH=CH-phenyl, -O(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>, -CNR<sup>b</sup>R<sup>c</sup>, -NHCR<sup>b</sup>,

 $\hbox{-NH(CH$_2$)}_p \hbox{NR}^b \hbox{R}^c, \hbox{-N(C$_1$-C$_6$alkyl)(CH$_2$)}_p \hbox{NR}^b \hbox{R}^c,$ 

R8 is COOH, tetrazolyl, -SO<sub>2</sub>Rd, or -CONHSO<sub>2</sub>Rd;

 $R^b$  and  $R^c$  are independently hydrogen,  $-C_1$ - $C_6$  alkyl,  $-(CH_2)_m$ -phenyl, or Rb and Rc taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl,

-107-

imidazolyl, piperazinyl, 4-C<sub>1</sub>-C<sub>6</sub> alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;

Rd is hydrogen, -C<sub>1</sub>-C<sub>6</sub> alkyl, -CF<sub>3</sub>, or phenyl;

m is 0 to 5 inclusive;

p is 1 to 5 inclusive;

A is CH or N;

 $R^1$  and  $R^2$ , when adjacent to one another, can be methylene-dioxy; or the pharmaceutically acceptable salts thereof.

- 2. The method of Claim 1 wherein
- 10 Ra is hydrogen;

5

15

25

n is 2; and

R<sup>3</sup> and R<sup>4</sup> are hydrogen.

3. The method of Claim wherein

Ra is hydrogen;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

n is 2 to 5 inclusive.

4. The method of Claim \( \) wherein

Ra is hydrogen;

n is 2;

- 20 R<sup>3</sup> and R<sup>4</sup> are hydrogen; and
  - $R^1,\,R^2,\,$  and  $R^7$  are independently chlorine, -N(CH2CH3)2, -OH, CH3-,

fluorine, -CF3, phenyl, hydrogen, -OCH2 phenyl,

-O(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>3</sub>)<sub>2</sub>, -O phenyl, -O(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>,

-CH(CH2OCH2CH3)2, pyrrolyl, -CH=CH-phenyl,

-OCH<sub>2</sub>- substituted phenyl, pyrrozolyl, or -N(phenyl)<sub>2</sub>.

20

I

10009611.052002

5. The method of Claim Nwherein

Ra is hydrogen;

n is 3, 4, or 5;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

R<sup>1</sup>, R<sup>2</sup>, and R<sup>7</sup> are independently chlorine or hydrogen.

6. The method of Claim I wherein

Ra is hydrogen;

n is 2;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

10 R<sup>5</sup>, R<sup>6</sup>, and R<sup>8</sup> are independently hydrogen, -CO<sub>2</sub>H, -NO<sub>2</sub>, -OCH<sub>3</sub>, imidazolyl, -CN, fluorine, -CH<sub>3</sub>, -CF<sub>3</sub>, halogen, -NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -NH<sub>2</sub>, or pyrrolyl.

7. The method of Claim I wherein

Ra is hydrogen;

15 n is 2;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

 $R^5$  is -CO<sub>2</sub>H.

8. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Formula I

wherein

Ra is hydrogen;

n is 1 to 5 inclusive;

WO 00/76489 PCT/US00/15071

-109-

R<sup>3</sup> and R<sup>4</sup> are hydrogen;

5

15

20

25

 $R^1$ ,  $R^7$ , and  $R^2$  are independently chlorine, -N(CH2CH3)2, -OH, CH3-,

fluorine, -CF3, phenyl, hydrogen, -OCH2 phenyl,

- -O(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>3</sub>)<sub>2</sub>, -O phenyl, -O(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>,
- -CH(CH2OCH2CH3)2, pyrrolyl, -CH=CH-phenyl,
- -N[(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>]<sub>2</sub>, substituted phenyl, -OCH<sub>2</sub>-substituted phenyl, pyrazolyl, or -N(phenyl)<sub>2</sub>;
- R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, -CO<sub>2</sub>H, -NO<sub>2</sub>, -OCH<sub>3</sub>, imidazolyl, -CN, fluorine, -CH<sub>3</sub>, -CF<sub>3</sub>, or pyrrolyl;
- 10 R<sup>8</sup> is COOH or tetrazolyl;
  or the pharmaceutically acceptable salts thereof.
  - 9. The method of Claim wherein the compound of Formula I is:
    - 2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino-benzoic acid;
    - 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-5-nitrobenzoic acid;
    - 2-{4-[4-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-4-methoxy-5-nitrobenzoic acid;
      - 2-{4-[2-(3,4-Dihydroxy-phenyl)-ethyl]-phenylamino}benzoic acid;
      - 2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]phenylamino}benzoic acid;
    - 2-{4-[2-(3,4,5-Trihydroxy-phenyl)-ethyl]phenylamino}benzoic acid;
    - 2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-methoxy-5-nitrobenzoic acid;
    - 2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-imidazo-1-yl-5-nitrobenzoic acid;
      - 2-{4-[3-(3,4-Dichlorophenyl)-propyl]phenylamino}benzoic acid;
      - $\hbox{$2-\{4-[4-(3,4-Dichlorophenyl)]$ phenylamino}$ benzoic acid;$
    - 2-{4-[4-(3,4-Dichloro-phenyl)-butyl]-phenylamino}-5-nitrobenzoic acid;

2-{4-[4-(3,4-Dichlorophenyl)-butyl]phenylamino}-3,5-dinitrobenzoic acid: 2-{4-[5-(3,4-Dichlorophenyl)pentyl]phenylamino}-5-nitrobenzoic acid; 5 2-{4-[5-(3,4-Dichloro-phenyl)pentyl]phenylamino}-4-methoxy-5-nitrobenzoic acid; 2-[4-(3,4-Dichloro-benzyl)-phenylamino]-benzoic acid; 2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl]-phenylamino}-5-nitrobenzoic acid; 10 2-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-phenylamino}-5-nitrobenzoic acid: 2-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}benzoic acid; 2-[4-(2-Biphenyl-4-yl-ethyl)-phenylamino]-5-nitro-benzoic acid; 15 5-Nitro-2-(4-phenethyl-phenylamino)-benzoic acid; 2-(4-Phenethyl-phenylamino)-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methoxybenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-terephthalic 20 acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methylbenzoic acid; 4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-isophthalic acid; 25 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5methanesulfonyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-imidazol-1yl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-nitro-30 benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-nitrobenzoic acid;

10009611.052002

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-nitro-

benzoic acid; 5-Cyano-2-{4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino}benzoic acid; 5 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4,6-difluorobenzoic acid; 6-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-2,3-difluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-fluoro-10 benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-fluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-methylbenzoic acid; 15 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-fluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3,5-difluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-20 trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5trifluoromethyl-benzoic acid; 25 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-pyrrol-1-ylbenzoic acid; 2-{4-[2-(4-Benzyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-(4-{2-[4-(3-Dimethylamino-propoxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 30 2-{4-[2-(4-Diethylamino-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Phenoxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Octyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid;

10009511.05e002

	2-(4-{2-[4-(2-Ethoxy-1-ethoxymethyl-ethyl)-phenyl]-ethyl}-
	phenylamino)-benzoic acid;
	2-{4-[2-(4-Pyrrol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(4-Styryl-phenyl)-ethyl]-phenylamino}-benzoic acid;
5	2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]-phenylamino}-benzoic
	acid;
	2-{4-[2-(4'-Ethyl-biphenyl-4-yl)-ethyl]-phenylamino}-benzoic
	acid;
	2-{4-[2-(4-Octyl-phenyl)-ethyl]-phenylamino}-benzoic acid;
10	2-(4-{2-[3-(3,5-Dichloro-phenoxy)-phenyl]-ethyl}-phenylamino)-
	benzoic acid;
	2-(4-{2-[4-(2-Chloro-6-fluoro-benzyloxy)-phenyl]-ethyl}-
	phenylamino)-benzoic acid;
	2-{4-[2-(4-Pyrazol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic
15	acid;
	2-{4-[2-(4-Diphenylamino-phenyl)-ethyl]-phenylamino}-benzoic
	acid;
	2-(4-{2-[4-(3,4-Dichloro-benzyloxy)-phenyl]-ethyl}-
	phenylamino)-benzoic acid;
20	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-amino-
	benzoic acid;
•	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-
	trifluoromethyl-benzoic acid;
	2-{4-[2-(3,4-Dichlorophenyl)]phenylamino}-5-nitrobenzoic acid;
25	2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-5-nitrobenzoic
	acid;
	2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl] phenylamino}-5-
	nitrobenzoic acid;
	2-[[4-[2-(4-Chloro-3-trifluoromethylphenyl)ethyl]phenyl]amino-
30	benzoic acid; or
	2-[4-(3,4-Dichlorophenyl)phenyl]aminobenzoic acid.

iooogeil.oseooe

-113-

10. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid protein an amyloid protein aggregation inhibiting amount of a compound of Formula I

wherein

0

Ra is hydrogen, C1-C6 alkyl, or -CC1-C6 alkyl;

n is 0 to 5 inclusive;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently hydrogen, halogen,
-OH, -NH<sub>2</sub>, NR<sup>b</sup>R<sup>c</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -NO<sub>2</sub>, -OC<sub>1</sub>-C<sub>12</sub>
alkyl, -C<sub>1</sub>-C<sub>8</sub> alkyl, -CF<sub>3</sub>, -CN, -OCH<sub>2</sub> phenyl, -OCH<sub>2</sub>-substituted phenyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, -O-phenyl, -O-substituted phenyl,

15

10

5

-CH=CH-phenyl, -O(CH<sub>2</sub>) $_p$ NR $^b$ R $^c$ , -CNR $^b$ R $^c$ , -NHCR $^b$ ,

-NH(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>,

$$\begin{array}{c} -\text{CH}_2\text{OC}_1\text{-C}_6 \text{ alkyl} \\ -\text{CH}_2\text{OC}_1\text{-C}_6 \text{ alkyl} \end{array};$$

20

R8 is COOH, tetrazolyl, -SO<sub>2</sub>Rd, or -CONHSO<sub>2</sub>Rd;

R<sup>b</sup> and R<sup>c</sup> are independently hydrogen, -C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, or R<sup>b</sup> and R<sup>c</sup> taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C<sub>1</sub>-C<sub>6</sub> alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;

25

5

10

20

25

oll.osaco

-114-

 $R^d$  is hydrogen,  $-C_1$ - $C_6$  alkyl,  $-CF_3$ , or phenyl;

m is 0 to 5 inclusive;

p is 1 to 5 inclusive;

A is CH or N;

R<sup>1</sup> and R<sup>2</sup>, when adjacent to one another, can be methylene-dioxy; or the pharmaceutically acceptable salts thereof.

11. The method of Claim 10 wherein

Ra is hydrogen;

n is 2; and

R<sup>3</sup> and R<sup>4</sup> are hydrogen.

12. The method of Claim 10 wherein

Ra is hydrogen;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

n is 2 to 5 inclusive.

15 13. The method of Claim 10 wherein

Ra is hydrogen;

n is 2;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

 $R^1$ ,  $R^2$ , and  $R^7$  are independently chlorine, -N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -OH, CH<sub>3</sub>-,

fluorine, -CF3, phenyl, hydrogen, -OCH2 phenyl,

-O(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>3</sub>)<sub>2</sub>, -O phenyl, -O(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>,

-CH(CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, pyrrolyl, -CH=CH-phenyl,

-OCH<sub>2</sub>-substituted phenyl, pyrazolyl, or -N(phenyl)<sub>2</sub>.

14. The method of Claim 10 wherein

I

vii oseoce

1000

Ra is hydrogen;

n is 3, 4, or 5;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

R<sup>1</sup>, R<sup>2</sup>, and R<sup>7</sup> are independently chlorine or hydrogen.

5 15. The method of Claim 10 wherein

Ra is hydrogen;

n is 2;

10

15

20

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, -CO<sub>2</sub>H, -NO<sub>2</sub>, -OCH<sub>3</sub>, imidazolyl, -CN, fluorine, -CH<sub>3</sub>, -CF<sub>3</sub>, halogen,

-NH-C $_1$ -C $_6$  alkyl, -N(C $_1$ -C $_6$ alkyl) $_2$ , -NH $_2$ , or pyrrolyl.

16. The method of Claim 10 wherein

Ra is hydrogen;

n is 2;

R<sup>3</sup> and R<sup>4</sup> are hydrogen; and

 $R^8$  is -CO<sub>2</sub>H.

17. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid protein an amyloid protein aggregation inhibiting amount of a compound of Formula I

$$\begin{array}{c|c}
R^{1} & R^{5} \\
R^{7} & R^{2}
\end{array}$$

$$\begin{array}{c|c}
(CH_{2})_{n} & R^{4} & R^{a} & R^{6}
\end{array}$$

wherein

Ra is hydrogen;

n is 1 to 5 inclusive;

10

15

20

25

10009 11 .oseooe

R<sup>3</sup> and R<sup>4</sup> are hydrogen;

 $R^1,\,R^7,\,$  and  $R^2$  are independently chlorine, -N(CH2CH3)2, -OH, CH3-,

fluorine, -CF3, phenyl, hydrogen, -OCH2 phenyl,

-O(CH<sub>2</sub>)<sub>3</sub>N(CH<sub>3</sub>)<sub>2</sub>, -O phenyl, -O(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>,

-CH(CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, pyrrolyl, -CH=CH-phenyl,

-N[(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>]<sub>2</sub>, substituted phenyl, -OCH<sub>2</sub>-substituted phenyl, pyrazolyl, or -N(phenyl)<sub>2</sub>;

 $R^5$  and  $R^6$  are independently hydrogen, -CO<sub>2</sub>H, -NO<sub>2</sub>, -OCH<sub>3</sub>, imidazolyl, -CN, fluorine, -CH<sub>3</sub>, -CF<sub>3</sub>, or pyrrolyl;

R<sup>8</sup> is COOH or tetrazolyl;

A is CH or N;

R<sup>1</sup> and R<sup>2</sup>, when adjacent to one another, can be methylene-dioxy; or the pharmaceutically acceptable salts thereof.

18. The method of Claim 17 wherein the compound of Formula I is:

2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-5-nitrobenzoic acid;

2-{4-[4-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-4-methoxy-5-nitrobenzoic acid;

2-{4-[2-(3,4-Dihydroxy-phenyl)-ethyl]-phenylamino}benzoic acid;

2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]phenylamino}benzoic acid;

2-{4-[2-(3,4,5-Trihydroxy-phenyl)-ethyl]phenylamino}benzoic acid;

2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-methoxy-5-nitrobenzoic acid;

2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-imidazo-1-yl-5-nitrobenzoic acid;

2-{4-[3-(3,4-Dichlorophenyl)-propyl]phenylamino}benzoic acid;

2-{4-[4-(3,4-Dichlorophenyl)butyl]phenylamino}benzoic acid;

-117-

2-{4-[4-(3,4-Dichloro-phenyl)-butyl}-phenylamino}-5-nitrobenzoic acid; 2-{4-[4-(3,4-Dichlorophenyl)-butyl]phenylamino}-3,5-dinitrobenzoic acid; 5 2-{4-[5-(3,4-Dichlorophenyl)pentyl]phenylamino}-5-nitrobenzoic acid; 2-{4-[5-(3,4-Dichloro-phenyl)pentyl]phenylamino}-4-methoxy-5-nitrobenzoic acid; 2-[4-(3,4-Dichloro-benzyl)-phenylamino]-benzoic acid; 2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl]-phenylamino}-5-nitro-10 benzoic acid; 2-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-phenylamino}-5-nitrobenzoic acid; 2-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}-15 benzoic acid: 2-[4-(2-Biphenyl-4-yl-ethyl)-phenylamino]-5-nitro-benzoic acid; 5-Nitro-2-(4-phenethyl-phenylamino)-benzoic acid; 2-(4-Phenethyl-phenylamino)-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methoxy-20 benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-terephthalic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methylbenzoic acid; 25 4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-isophthalic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5methanesulfonyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-imidazol-1-30 yl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-nitrobenzoic acid;

PCT/US00/15071

-118-

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-nitrobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-nitrobenzoic acid; 5 5-Cyano-2-{4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino}benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4,6-difluorobenzoic acid; 6-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-2,3-difluoro-10 benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-fluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-fluorobenzoic acid; 15 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-methylbenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-fluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3,5-difluoro-20 benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6trifluoromethyl-benzoic acid; 25 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-pyrrol-1-ylbenzoic acid; 2-{4-[2-(4-Benzyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 30 2-(4-{2-[4-(3-Dimethylamino-propoxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-(4-Diethylamino-phenyl)-ethyl]-phenylamino}-benzoic acid;

looosil osecoe

2-{4-[2-(4-Phenoxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Octyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-(4-{2-[4-(2-Ethoxy-1-ethoxymethyl-ethyl)-phenyl}-ethyl}phenylamino)-benzoic acid; 5 2-{4-[2-(4-Pyrrol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Styryl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4'-Ethyl-biphenyl-4-yl)-ethyl]-phenylamino}-benzoic 10 acid; 2-{4-[2-(4-Octyl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-(4-{2-[3-(3,5-Dichloro-phenoxy)-phenyl]-ethyl}-phenylamino)benzoic acid; 2-(4-{2-[4-(2-Chloro-6-fluoro-benzyloxy)-phenyl]-ethyl}-15 phenylamino)-benzoic acid; 2-{4-[2-(4-Pyrazol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Diphenylamino-phenyl)-ethyl]-phenylamino}-benzoic acid; 20 2-(4-{2-[4-(3,4-Dichloro-benzyloxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-[(3,4-Dichlorophenyl)propyl]phenylamino}-5-nitrobenzoic acid; 2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl] phenylamino}-5-25 nitrobenzoic acid; 2-[[4-[2-(4-Chloro-3-trifluoromethylphenyl]ethyl]phenyl]aminobenzoic acid; or 2-[4-(3,4-Dichlorophenyl)phenyl]aminobenzoic acid. 19. The compounds: 30 2-{4-[4-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-4-methoxy-

2-{4-[2-(3,4-Dihydroxy-phenyl)-ethyl]-phenylamino}benzoic acid;

5-nitrobenzoic acid;

10009611.052002

-120-

		2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]phenylamino}benzoic acid; 2-{4-[2-(3,4,5-Trihydroxy-phenyl)-ethyl]phenylamino}benzoic acid;
		2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-methoxy-
5		5-nitrobenzoic acid;
		2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}-4-imidazo-
		1-yl-5-nitrobenzoic acid; or
		2-{4-[4-(3,4-Dichlorophenyl)butyl]phenylamino}benzoic acid.
	20.	The compounds:
10		2-{4-[4-(3,4-Dichloro-phenyl)-butyl]-phenylamino}-5-nitro-
		benzoic acid;
		2-{4-[4-(3,4-Dichlorophenyl)-butyl]phenylamino}-3,5-
		dinitrobenzoic acid;
		2-{4-[5-(3,4-Dichlorophenyl)pentyl]phenylamino}-5-nitrobenzoic
15		acid;
		2-{4-[5-(3,4-Dichloro-phenyl)pentyl]phenylamino}-4-methoxy-
		5-nitrobenzoic acid;
		2-[4-(3,4-Dichloro-benzyl)-phenylamino]-benzoic acid;
		2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl]-phenylamino}-5-nitro-
20		benzoic acid;
		2-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-phenylamino}-5-nitro-
		benzoic acid;
		2-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}-
		benzoic acid;
25		2-[4-(2-Biphenyl-4-yl-ethyl)-phenylamino]-5-nitro-benzoic acid;
		5-Nitro-2-(4-phenethyl-phenylamino)-benzoic acid.
		2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-amino-
		benzoic acid;
		2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-
30		trifluoromethyl-benzoic acid; or
		2-{4-[2-(3,4-Dichlorophenyl)]phenylamino}-5-nitrobenzoic acid.

10

15

20

25

30

10009611.052002

## 21. The compounds:

2-(4-Phenethyl-phenylamino)-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methoxy-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-terephthalic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methylbenzoic acid;

4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-isophthalic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methanesulfonyl-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-imidazol-1-yl-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-nitrobenzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-nitrobenzoic acid; or

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-nitro-benzoic acid.

## 22. The compounds:

5-Cyano-2-{4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4,6-difluoro-benzoic acid;

6-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-2,3-difluoro-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-fluoro-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-fluorobenzoic acid;

10

15

20

25

30

-122-	
2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-methyl-	
enzoic acid;	
2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-fluoro-	
enzoic acid;	
2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3,5-difluoro-	
enzoic acid;	
2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-	
rifluoromethyl-benzoic acid;	
2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-	
ifluoromethyl-benzoic acid;	
2-{4-[3-(4-Diethylaminophenyl)propyl]phenylamino}benzoic acid	1;
2-{4-[3-(4-Nitrophenyl)propyl]phenylamino}benzoic acid;	
2-{4-[3-(3-Nitrophenyl)propyl]phenylamino}benzoic acid;	
2-{4-[3-(4-Aminophenyl)propyl]phenylamino}benzoic acid;	
2-{4-[3-(3-Aminophenyl)propyl]phenylamino}benzoic acid;	
2-{4-[2-(4-Aminophenyl)phenylamino}benzoic acid;	
2-{4-[2-(4-Dipropylaminophenyl)ethyl]phenylamino}benzoic acid	i
nonohydrochloride;	
2-{4-[2-(4-Diethylaminophenyl)ethyl]phenylamino}benzoic acid	
nonohydrochloride monohydrate;	
2-{4-[3-(3-Dipropylaminophenyl)propyl]phenylamino}benzoic	
cid;	
2-{4-[3-(3-Dimethylaminophenyl)propyl]phenylamino}benzoic	
cid;	
2-{4-[3-(4-Ethylaminophenyl)propyl]phenylamino}benzoic acid;	
2-(N-{4-[3-(4-Diethylaminophenyl)propyl]phenyl}-N-	
thylamino)benzoic acid;	
2-{4-[2-(3-Dibenzylaminophenyl)ethyl]phenylamino}benzoic acid	d;
2-{4-[3-(3-Diethylaminophenyl)propyl]phenylamino}benzoic acid	d;
2-{4-[2-(3-Aminophenyl)ethyl]phenylamino}benzoic acid;	
2-{4-[3-(4-Dimethylaminophenyl)propyl]phenylamino}benzoic	
cid;	

2-{4-[2-(4-Acetylaminophenyl)ethyl]phenylamino}benzoic acid;

loogil.oseoge

2-{4-[2-(3-Acetylaminophenyl)ethyl]phenylamino}benzoic acid;

2-{4-[2-(3-Dipropylaminophenyl)ethyl]phenylamino}benzoic acid monohydrochloride; 2-{4-[2-(3-Dibutylaminophenyl)ethyl]phenylamino}benzoic acid 5 monohydrochloride; 2-{4-[3-(4-Acetylaminophenyl)propyl]phenylamino}benzoic acid; 2-{4-[3-(3-Acetylaminophenyl)propyl]phenylamino}benzoic acid; 2-{4-[2-(3-Diethylaminophenyl)ethyl]phenylamino}benzoic acid monohydrochloride; 10 2-{4-[2-(3-Piperidin-1-ylphenyl)ethyl]phenylamino}benzoic acid monohydrochloride; 2-{4-[3-(4-Dipropylaminophenyl)propyl]phenylamino}benzoic acid; 2-{4-[3-(4-Dibutylaminophenyl)propyl]phenylamino}benzoic acid; 15 2-{4-[3-(3-Dibutylaminophenyl)propyl]phenylamino}benzoic acid; 2-(4-{3-[4-(1H-Pyrrol-1-yl)phenyl]propyl}phenylamino)benzoic acid; 2-{4-[3-(4-Piperidin-1-ylphenyl)propyl]phenylamino}benzoic acid; 2-{4-[3-(4-Diethylcarbamoylphenyl)propyl]phenylamino}benzoic 20 acid; 2-{4-[3-(4-Carboxyphenyl)propyl]phenylamino}benzoic acid; 2-{4-[3-(4-Diethylaminomethylphenyl)propyl]phenylamino} benzoic acid; 2-{4-[3-(4-Propylaminophenyl)propyl]phenylamino}benzoic acid; 2-{4-[3-(3-Propylaminophenyl)propyl]phenylamino}benzoic acid; 25 2-{4-[3-(4-Pyrrolidin-1-yl-phenyl)-propyl]-phenylamino}-benzoic acid; 2-{4-[3-(3-Piperidin-1yl-phenyl)-propyl]-phenylamino}-benzoic acid; 30 {5-[(1-Butyl-1,2,3,4-tetrahydro-6-quinolyl)methylidene]-4-oxo-2thioxothiazolidin-3-yl}acetic acid; {5-[(1-Butyl-2,3-dihydro-1H-indol-5-yl)methylidene]-4-oxo-2-

thioxothiazolidin-3-yl}acetic acid:

acid;

andosil osedoe

3-{5-[(1-Butyl-1,2,3,4-tetrahydroquinolin-6-yl)methylidene]-4-

oxo-2-thioxo-thiazolidin-3-yl}propanoic acid; 4-{5-[(1-Butyl-1,2,3,4-tetrahydroquinolin-6-yl)methylidene]-4oxo-2-thioxo-thiazolidin-3-yl}butanoic acid; 5 2-{4-[3-(3,4-Dichloro-phenyl)-propyl]phenylamino}-5-methylbenzoic acid; N-(2-{4-[3-(3,4-Dichloro-phenyl)-propyl]-phenylamino}-benzoyl)methanesulofnamime; 2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl]phenylamino}-5-nitro-10 benzoic acid; 2-[4-(2-Biphenyl-4-yl-ethyl)-phenylamino]-5-nitro-benzoic acid; 2-{4-[2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}-5-nitro-benzoic acid; 5-Amino-2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-15 benzoic acid; 5-Nitro-2-(4-phenethyl-phenylamino)-benzoic acid; 2-{4-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}benzoic acid; 2-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-phenylamino}-5-nitro-20 benzoic acid; {4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-[2-(1H-tetrazol-5-yl)phenyl]-amine; 2-{4-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-ethyl]-phenylamino}-5-nitro-benzoic acid; 25 2-(4-Phenethyl-phenylamino)-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-fluorobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-nicotinic acid; 2-{4-[2-(3-Chloro-phenyl)-ethyl]-phenylamino}-5-nitro-benzoic 30 acid; 2-{4-[2-(4-Chloro-phenyl)-ethyl]-phenylamino}-5-nitro-benzoic

10

15

20

25

30

benzoic acid;

	-125-
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methyl-
benzo	ic acid;
	2-{4-[2-(2-Chloro-phenyl)-ethyl]-phenylamino}-5-nitro-benzoic
acid;	
	2-{4-[2-(2,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-nitro-
benzo	ic acid;
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-6-
trifluo	romethyl-benzoic acid;
	2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]-phenylamino}-5-nitro-
benzo	ic acid;
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-
dimetl	hylamino-benzoic acid;
	2-{4-[2-(3,5-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-(4-{2-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-phenyl]-ethyl}-
pheny	lamino)-benzoic acid;
	2-(3',5'-Dichloro-3-methyl-biphenyl-4-ylamino)-benzoic acid;
	2-(3',5'-Dibromo-3-methyl-biphenyl-4-ylamino)-benzoic acid;
	2-(4-1,3-Benzodioxol-5-yl-2-methyl-phenylamino)-benzoic acid;
	2-(2,2',4'-Trichloro-biphenyl-4-ylamino)-benzoic acid;
	2-(2-Chloro-3',4'-difluoro-biphenyl-4-ylamino)-benzoic acid;
	2-(3'-Bromo-2-chloro-biphenyl-4-ylamino)-benzoic acid;
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-nitro-
benzo	ic acid;
	3-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	5-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-isophthalic
acid;	
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4,5-
dimetl	hoxy-benzoic acid;
	2-{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenylamino}-3-nitro-

loogil.oseooe

3-{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenylamino}-benzoic acid; 5-{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenylamino}isophthalic acid; 5 2-{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenylamino}-benzoic acid; 4-(4-{2-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-5-10 methoxy-benzoic acid; 2-{4-[2-(3-Methoxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(3-Bromo-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(3-Fluoro-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-methoxy-15 benzoic acid; 4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-nicotinic acid; 2-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-benzoic acid; or 2-{4-[2-(3-Fluoro-4-methyl-phenyl)-ethyl]-phenylamino}-benzoic 20 acid. 23. The compounds: 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-pyrrol-1-yl-25 benzoic acid; 2-{4-[2-(4-Benzyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-(4-{2-[4-(3-Dimethylamino-propoxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-(4-Diethylamino-phenyl)-ethyl]-phenylamino}-benzoic 30 acid; 2-{4-[2-(4-Phenoxy-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Octyloxy-phenyl)-ethyl]-phenylamino}-benzoic acid;

24.

5

10

15

20

25

30

PCT/US00/15071

-127-2-(4-{2-[4-(2-Ethoxy-1-ethoxymethyl-ethyl)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-(4-Pyrrol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic acid; or 2-{4-[2-(4-Styryl-phenyl)-ethyl]-phenylamino}-benzoic acid. The compounds: 2-{4-[2-(4-Dibutylamino-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4'-Ethyl-biphenyl-4-yl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Octyl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-(4-{2-[3-(3,5-Dichloro-phenoxy)-phenyl]-ethyl}-phenylamino)benzoic acid; 2-(4-{2-[4-(2-Chloro-6-fluoro-benzyloxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-(4-Pyrazol-1-yl-phenyl)-ethyl]-phenylamino}-benzoic acid; 2-{4-[2-(4-Diphenylamino-phenyl)-ethyl}-phenylamino}-benzoic acid; 2-(4-{2-[4-(3,4-Dichloro-benzyloxy)-phenyl]-ethyl}phenylamino)-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-aminobenzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5trifluoromethyl-benzoic acid; 2-{4-[2-(3,4-Dichlorophenyl)]phenylamino}-5-nitrobenzoic acid; 2-{4-[2-[(3,4-Dichlorophenyl)propyl]phenylamino}-5-nitrobenzoic acid; 2-{4-[2-(3,4-Dimethyl-phenyl)-ethyl] phenylamino}-5nitrobenzoic acid;

2-[4-(3,4-Dichlorophenyl)phenyl]aminobenzoic acid.

WO 00/76489 PCT/US00/15071

-128-

- 25. 2-[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino-benzoic acid or a pharmaceutically acceptable salt thereof.
- 26. 2-{4-[3-(3,4-Dichlorophenyl)propyl]phenylamino}benzoic acid or a pharmaceutically acceptable salt thereof.
- 5 27. A compound which is selected from:

10

15

20

25

30

2-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-5-nitro-benzoic acid;

4-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-benzoic acid;

4-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-3-methoxy-benzoic acid;

2-{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenylamino}-5-methoxy-benzoic acid;

{4-[2-(3-Chloro-4-methyl-phenyl)-ethyl]-phenyl}-(2-methoxy-5-nitro-phenyl)-amine;

2-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-3-nitro-benzoic acid;

3-{4-[3-(4-Diethylamino-phenyl)-propyl]-phenylamino}-benzoic acid;

2-{4-[2-(3,4-Dimethoxy-phenyl)-ethyl]-phenylamino}-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid monosodium;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid monopotassium;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid calcium salt (1:1);

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoate-2-hydroxy-1,1-bis-hydroxymethyl-ethyl-ammonium;

2-{4-[4-(3,4-Dichloro-phenyl)-butyl]-phenylamino}-5-methoxy-benzoic acid;

-129-

	2-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{3-[2-(4-Chloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{3-[2-(3,4-Dimethyl-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(2,4-Dimethoxy-phenyl)-ethyl]-phenylamino}-benzoic
5	acid;
	2-{4-[2-(2-Chloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(2-Hydroxy-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(3-Chloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-[4-(2-Biphenyl-4-yl-ethyl)-phenylamino]-benzoic acid;
10	2-{4-[2-(2,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	3-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamino}-benzoic
	acid;
15	2-{4-[2-(4-Phenoxy-phenyl)-ethyl]-phenylamino}-benzoic acid;
	2-{4-[5-(3,4-Dichloro-phenyl)-pentyl]-phenylamino}-benzoic acid;
	2-(3',5'-Dichloro-biphenyl-4-ylamino)-benzoic acid;
	4-{4-[3-(3,4-Dichloro-phenyl)-propyl]-phenylamino}-2-methoxy-
	5-nitro-benzoic acid;
20	2-{4-[3-(3,4-Dichloro-phenyl)-propyl]-phenylamino}-5-fluoro-
	benzoic acid;
	5-Amino-2-{4-[5-(3,4-dichloro-phenyl)-pentyl]-phenylamino}-
	benzoic acid;
	N-(2-{4-[3-(3,4-Dichloro-phenyl)-propyl]-phenylamino}-benzoyl)-
25	C,C,C-trifluoro-methanesulfonamide;
	N-(2-{4-[3-(3,4-Dichloro-phenyl)-propyl]-phenylamino}-benzoyl)-
	benzenesulfonamide;
	2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-
	trifluoromethyl-benzoic acid;
30	4-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-isophthalic
	acid;

10

15

20

25

10009411.058002

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-4-trifluoromethyl-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-3-trifluoromethyl-benzoic acid;

2-({4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-methyl-amino)-5-dimethylamino-benzoic acid;

2-({4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-methyl-amino)-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-dipropylamino-benzoic acid;

5-Dibutylamino-2-{4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino}-benzoic acid;

2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]-phenylamino}-5-diethylamino-benzoic acid;

2,2'-[1,2-Ethanediylbis (4,1-phenyleneimino)]bis-benzoic acid; and 4-[3-[4-(Diethylamino)phenyl]propyl]-N-(2-methoxy-5-nitrophenyl)-benzinamine

# 28. A method of imaging amyloid deposits, the method comprising:

a. introducing into a patient a detectable quantity of a labeled compound having the Formula I or a pharmaceutically acceptable salt thereof:

wherein

loogil.oseooe

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently hydrogen, halogen,
-OH, -NH<sub>2</sub>, NR<sup>b</sup>R<sup>c</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -NO<sub>2</sub>, -OC<sub>1</sub>-C<sub>12</sub>
alkyl, -C<sub>1</sub>-C<sub>8</sub> alkyl, -CF<sub>3</sub>, -CN, -OCH<sub>2</sub> phenyl, -OCH<sub>2</sub>-substituted phenyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, -O-phenyl, -O-substituted phenyl,

5

-CH=CH-phenyl, -O(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>, -CNR<sup>b</sup>R<sup>c</sup>, -NHCR<sup>b</sup>,
-NH(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>,

-CH<sub>2</sub>OC<sub>1</sub>-C<sub>6</sub> alkyl

-CH

CH<sub>2</sub>OC<sub>1</sub>-C<sub>6</sub> alkyl

10

R8 is COOH, tetrazolyl, -SO2Rd, or -CONHSO2Rd;

R<sup>b</sup> and R<sup>c</sup> are independently hydrogen, -C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, or R<sup>b</sup> and R<sup>c</sup> taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C<sub>1</sub>-C<sub>6</sub> alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;

15

Rd is hydrogen, -C1-C6 alkyl, -CF3, or phenyl;

m is 0 to 5 inclusive;

p is 1 to 5 inclusive;

A is CH or N;

20

R<sup>1</sup> and R<sup>2</sup>, when adjacent to one another, can be methylene-dioxy; or the pharmaceutically acceptable salts thereof.

- b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
- detecting the labeled compound associated with the amyloid deposits.

25

29. The method of Claim 28 wherein the patient has or is suspected to have Alzheimer's disease.

anooşıı.useone

- 30. The method of Claim 28 wherein the labeled compound is a radio labeled compound.
- 31. The method of Claim 28 wherein the labeled compound is detected using MRI.
- 5 32. The compounds:

10

15

20

2-[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino-benzoic acid; 2-{4-[2-(3,4-Dichloro-phenyl)-ethyl]phenylamino}-5-nitrobenzoic acid;

2-{4-[3-(3,4-Dichlorophenyl)-propyl]phenylamino}benzoic acid;

2-[4-[2-(4-Chloro-3-trifluoromethylphenyl]phenyl]aminobenzoic acid; and

- 2-{4-[3-(4-Diethylaminophenyl)propyl]phenylamino}benzoic acid.
- 33. A pharmaceutical formulation comprising a compound of Claim 19 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
- 34. A pharmaceutical formulation comprising a compound of Claim 20 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
- 35. A pharmaceutical formulation comprising a compound of Claim 21 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
  - 36. A pharmaceutical formulation comprising a compound of Claim 22 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.

15

20

I

- 37. A pharmaceutical formulation comprising a compound of Claim 23 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
- 38. A pharmaceutical formulation comprising a compound of Claim 24 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
- 39. A pharmaceutical formulation comprising a compound of Claim 25 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
- 10 40. A pharmaceutical formulation comprising a compound of Claim 26 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
  - 41. A pharmaceutical formulation comprising a compound of Claim 32 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.
  - 42. A compound of Formula I.

wherein

Ra is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, or -CC<sub>1</sub>-C<sub>6</sub> alkyl;

n is 0 to 5 inclusive;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently hydrogen, halogen,
-OH, -NH<sub>2</sub>, NR<sup>b</sup>R<sup>c</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -NO<sub>2</sub>, -OC<sub>1</sub>-C<sub>12</sub>

0

10

-134-

alkyl, - $C_1$ - $C_8$  alkyl, - $CF_3$ , -CN, - $OCH_2$  phenyl, - $OCH_2$ -substituted phenyl, - $(CH_2)_m$ -phenyl, -O-phenyl, -O-substituted phenyl,

-CH=CH-phenyl, -O(CH<sub>2</sub>)<sub>p</sub>NR<sup>b</sup>R<sup>c</sup>, -CNR<sup>b</sup>R<sup>c</sup>, -NHCR<sup>b</sup>,

 $-NH(CH_2)_pNR^bR^c$ ,  $-N(C_1-C_6alkyl)(CH_2)_pNR^bR^c$ ,

$$\begin{array}{c} \text{CH}_2\text{OC}_1\text{-C}_6 \text{ alkyl} \\ \text{-CH} \\ \text{CH}_2\text{OC}_1\text{-C}_6 \text{ alkyl} \end{array};$$

R<sup>8</sup> is COOH, tetrazolyl, -SO<sub>2</sub>R<sup>d</sup>, or -CONHSO<sub>2</sub>R<sup>d</sup>;

R<sup>b</sup> and R<sup>c</sup> are independently hydrogen, -C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, or

R<sup>b</sup> and R<sup>c</sup> taken together with the nitrogen atom to which they are
attached form a cyclic ring selected from piperidinyl, pyrrolyl,
imidazolyl, piperazinyl, 4-C<sub>1</sub>-C<sub>6</sub> alkylpiperazinyl, morpholino,
thiomorpholino, decahydroisoquinoline, or pyrazolyl;

R<sup>d</sup> is hydrogen, -C<sub>1</sub>-C<sub>6</sub> alkyl, -CF<sub>3</sub>, or phenyl;

m is 0 to 5 inclusive;

p is 1 to 5 inclusive;

A is CH or N;

R<sup>1</sup> and R<sup>2</sup>, when adjacent to one another, can be methylene-dioxy; or the pharmaceutically acceptable salts thereof.

A pharmaceutical formulation comprising a compound of Claim 42 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.